Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
| Revenue (TTM) | $4.49B |
| Gross Profit (TTM) | $3.05B |
| EBITDA | $1.16B |
| Operating Margin | 21.10% |
| Return on Equity | 32.30% |
| Return on Assets | 8.67% |
| Revenue/Share (TTM) | $29.57 |
| Book Value | $18.80 |
| Price-to-Book | 11.79 |
| Price-to-Sales (TTM) | 7.33 |
| EV/Revenue | 7.75 |
| EV/EBITDA | 25.15 |
| Quarterly Earnings Growth (YoY) | -9.40% |
| Quarterly Revenue Growth (YoY) | 9.40% |
| Shares Outstanding | $151.00M |
| Float | $149.53M |
| % Insiders | 0.20% |
| % Institutions | 106.53% |
Volatility is currently contracting
Illumina (ILMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 2026 results Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China ("ROW1 organic revenue growth") GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31 "Illumina delivered strong results during the second quarter.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ILMN and any ticker you trade — then tracks every position and per-strategy win rate.
